ArticleCurrent medical science2020

4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition.

Xin-Ying Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.